Improving the efficacy of drug development: Another milestone agreement for biosensor technology - Improving the efficacy of drug development: Another milestone agreement for biosensor technology - Research Institute of the McGill University Health Centre
Banner Core Facilities
Biosensor technology co-developed by Dr. Stéphane Laporte, a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), and Dr. Michel Bouvier of the Institute for Research in Immunology and Cancer, Université de Montréal, has reached another important milestone with buy-in from the pharmaceutical giant Pfizer.
A set of powerful new biosensors that facilitates profiling of more effective and safer drug candidates, the technology was licenced for exclusive commercialization by the company Domain Therapeutics in 2013. In late 2016 Alkermes, a biotechnology company, acquired rights to use the biosensors. Earlier this week Pfizer also signed an agreement to access this technology, to support the development of new drugs acting on G protein coupled receptors for novel therapeutic use. This is a clear signal that the pharmaceutical industry is adopting this innovative technology to improve the efficacy of the drug development process.
—April 27, 2017